186 related articles for article (PubMed ID: 22987142)
1. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.
Irazabal MV; Eirin A; Lieske J; Beck LH; Sethi S; Borland TM; Dillon JJ; Nachman PH; Nasr SH; Cornell LD; Leung N; Cattran DC; Fervenza FC
Nephrol Dial Transplant; 2013 Jan; 28(1):137-46. PubMed ID: 22987142
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy.
Bazzi C; Petrini C; Rizza V; Arrigo G; Beltrame A; Pisano L; D'Amico G
Am J Kidney Dis; 2001 Aug; 38(2):240-8. PubMed ID: 11479148
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency.
du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2006 Feb; 21(2):389-96. PubMed ID: 16234291
[TBL] [Abstract][Full Text] [Related]
4. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.
Roccatello D; Sciascia S; Di Simone D; Solfietti L; Naretto C; Fenoglio R; Baldovino S; Menegatti E
Autoimmun Rev; 2016 Jun; 15(6):529-38. PubMed ID: 26876383
[TBL] [Abstract][Full Text] [Related]
5. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.
Fervenza FC; Abraham RS; Erickson SB; Irazabal MV; Eirin A; Specks U; Nachman PH; Bergstralh EJ; Leung N; Cosio FG; Hogan MC; Dillon JJ; Hickson LJ; Li X; Cattran DC;
Clin J Am Soc Nephrol; 2010 Dec; 5(12):2188-98. PubMed ID: 20705965
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in idiopathic membranous nephropathy.
Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.
Beck LH; Fervenza FC; Beck DM; Bonegio RG; Malik FA; Erickson SB; Cosio FG; Cattran DC; Salant DJ
J Am Soc Nephrol; 2011 Aug; 22(8):1543-50. PubMed ID: 21784898
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy.
Busch M; Rüster C; Schinköthe C; Gerth J; Wolf G
Clin Nephrol; 2013 Aug; 80(2):105-13. PubMed ID: 23587125
[TBL] [Abstract][Full Text] [Related]
10. Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: a predictive marker of risk and drug responsiveness.
Bazzi C; Rizza V; Casellato D; Tofik R; Berg AL; Gallieni M; D'Amico G; Bakoush O
BMC Nephrol; 2014 May; 15():74. PubMed ID: 24886340
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy.
Peters HP; van den Brand JA; Wetzels JF
Neth J Med; 2009 Feb; 67(2):54-61. PubMed ID: 19299847
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
[TBL] [Abstract][Full Text] [Related]
13. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy.
van den Brand JA; Hofstra JM; Wetzels JF
Clin J Am Soc Nephrol; 2011 Dec; 6(12):2846-53. PubMed ID: 22157712
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for idiopathic membranous nephropathy: who can benefit?
Ruggenenti P; Chiurchiu C; Abbate M; Perna A; Cravedi P; Bontempelli M; Remuzzi G
Clin J Am Soc Nephrol; 2006 Jul; 1(4):738-48. PubMed ID: 17699281
[TBL] [Abstract][Full Text] [Related]
16. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis.
Bazzi C; Petrini C; Rizza V; Arrigo G; Napodano P; Paparella M; D'Amico G
Nephrol Dial Transplant; 2002 Nov; 17(11):1890-6. PubMed ID: 12401843
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Boyer-Suavet S; Andreani M; Lateb M; Savenkoff B; Brglez V; Benzaken S; Bernard G; Nachman PH; Esnault V; Seitz-Polski B
Front Immunol; 2019; 10():3069. PubMed ID: 31998325
[TBL] [Abstract][Full Text] [Related]
18. Albumin, IgG, retinol-binding protein, and alpha1-microglobulin excretion in childhood.
Lehrnbecher T; Greissinger S; Navid F; Pfüller H; Jeschke R
Pediatr Nephrol; 1998 May; 12(4):290-2. PubMed ID: 9655359
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
[TBL] [Abstract][Full Text] [Related]
20. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
